Invesco
TCRX icon

Invesco’s TScan Therapeutics TCRX Stock Holding History

Invesco’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,590
Closed -$28.4K – 3872
2025
Q1 		$28.4K Sell
20,590
-38
-0.2% -$82 ﹤0.01% 3731
2024
Q4 		$62.7K Buy
20,628
+2,612
+14% +$11.8K ﹤0.01% 3671
2024
Q3 		$89.7K Sell
18,016
-481,858
-96% -$2.91M ﹤0.01% 3631
2024
Q2 		$2.92M Buy
499,874
+11,459
+2% +$90.3K ﹤0.01% 2436
2024
Q1 		$3.88M Buy
+488,415
New +$3.07M ﹤0.01% 2377

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Invesco's TCRX Position: Q2 2025 in Review

Invesco sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 20,590 shares — an estimated $28.4K sold.

Invesco first reported a position in TCRX in Q1 2024 and held it in 5 quarters. The position peaked at $3.88M in Q1 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • Invesco reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Invesco sold 20,590 TScan Therapeutics shares in Q2 2025, an estimated $28.4K.
  • Invesco first reported a position in TScan Therapeutics in Q1 2024 and held it in 5 quarters.
  • Invesco's TScan Therapeutics position peaked at $3.88M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.